Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL-III in treatment-naive genotype 1b chronic hepatitis C
2012-003687-52Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Dec 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of paritaprevir, ritonavir, glecaprevir, dasabuvir and ribavirin in chronic hepatitis C (CHC) (2 arms), sponsored by Abbott Laboratories. Primary endpoint: Sustained virologic response at 12 weeks post-treatment. Started Dec 2012; status: completed.
02
Drugs
paritaprevirritonavirglecaprevirdasabuvirribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2012-003687-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003687-52.